Kimberly Homan, PhD

Genentech, Inc., San Francisco, USA


Kim is a Senior Director and Distinguished Scientist at Genentech where she heads the Complex in vitro Systems lab, a core group focused on employing new predictive tools to enhance clinical translational outcomes. She has prior experience holding key leadership positions in two biotech startups, one of which she co-founded while in graduate school at UT Austin. Prior to that, as a co-appointed postdoc at Roche and at the Wyss Institute in Harvard, Kim invented methods to bioprint human tissues and use them to model drug disposition, mode of action, and safety. She has ~50 peer reviewed publications and 16 patents and patent applications. Kim holds a B.S. degree in chemical engineering and Ph.D. in biomedical engineering; she is also a former United States Marine Corps officer and veteran.

On a more personal note, Kim is a staunch advocate for this OOC/MPS space and her group is doing the heavy lifting to incorporate models into routine use in pharma, helping to reduce our reliance on animals in drug testing. She is also advocating for more diverse human representation in these systems and believes that DEI work should start at the bench in preclinical drug development. She welcomes input and ideas from everyone on these topics.